A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity

Combinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclinical evaluation of CTX-8371, a protein construct which combines PD-1 and PD-L1 targeting in one bispecif...

全面介紹

書目詳細資料

發表在:	OncoImmunology
Main Authors:	Diana I. Albu, Benjamin J. Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben, Mei Su, Vivian Li, Eirene Ding, Jose Angel Gonzalo, Jason Kong, Ruturaj Jadhav, Nelly Kuklin, Alberto Visintin, Bing Gong, Thomas J. Schuetz
格式:	Article
語言:	英语
出版:	Taylor & Francis Group 2024-12-01
主題:	Cancer immunotherapy immuno-oncology
在線閱讀:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2316945